Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease

Journal of Diabetes Investigation

Volumn 5, Issue 2, 2014, Pages 170-175

  Kim, Bo Yeon ^a   Jung, Chan Hee ^a   Mok, Ji Oh ^a   Kang, Sung Koo ^a   Kim, Chul Hee ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Diabetes mellitus type 2; Diabetic angiopathies; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; C REACTIVE PROTEIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ALBUMINURIA; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; KOREA; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RETROSPECTIVE STUDY; SEX;

EID: 84896487952     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12139     Document Type: Article

References (31)

1. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
2. Day CP. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 2006; 6: 19-25.
3. Marchesini G, Marzocchi R, Agostini F, et al. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-427.
4. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
5. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530 e521; quiz e560.
6. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
7. Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006; 23: 403-409.
8. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-3546.
9. Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-2121.
10. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-240.
11. Targher G, Bertolini L, Rodella S, et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008; 51: 444-450.
12. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008; 19: 1564-1570.
13. Casoinic F, Sampelean D, Bǎdǎu C, et al. Nonalcoholic fatty liver disease-a risk factor for microalbuminuria in type 2 diabetic patients. Rom J Intern Med 2009; 47: 55-59.
14. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003; 88: 2300-2308.
15. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006; 368: 1681-1688.
16. Rhee SY, Woo JT, Chon S, et al. Characteristics of insulin resistance and insulin secretory capacity in Korean subjects with IFG and IGT. Diabetes Res Clin Pract 2010; 89: 250-255.
17. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
18. Samnegard B, Jacobson SH, Jaremko G, et al. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001; 60: 1258-1265.
19. Djemli-Shipkolye A, Gallice P, Coste T, et al. The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism 2000; 49: 868-872.
20. Kim BY, Jung CH, Mok JO, et al. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 2012; 49: 9-15.
21. Bo S, Cavallo-Perin P, Gentile L, et al. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 2000; 37: 125-129.
22. Inukai T, Matsutomo R, Tayama K, et al. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107: 40-45.
23. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009; 32: 301-305.
24. Targher G, Bertolini L, Scala L, et al. Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. Diabetes Care 2007; 30: e31- e32.
25. Abiru S, Migita K, Maeda Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int 2006; 26: 39-45.
26. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 1497-1502.
27. Albano E, Mottaran E, Vidali M, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005; 54: 987-993.
28. Ioannou GN, Weiss NS, Boyko EJ, et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006; 43: 1145-1151.
29. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-396.
30. Lu H, Zeng L, Liang B, et al. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res 2009; 40: 571-575.
31. Agarwal AK, Jain V, Singla S, et al. Prevalence of nonalcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India 2011; 59: 351-354.